As 2024 drew to a close, Englands NICE finalised its guidance for Mounjaro, recommending its use in the primary care setting, for treating adults with a body mass index (BMI) 35 kg/m2 and at least one weight-related co-morbidity, alongside a reduced-calorie diet and increased exercise, with no restriction on treatment duration, equating to a total eligible population of 3.4 million patients [5]
Reduced muscle mass partially explains that shift
Benefits for Tirzepatide Users Beyond gut protection, BPC-157 offers several advantages during weight loss protocols
The Company assumes no responsibility or liability for any misrepresentation of Your age
Take 1 capsule 3 times a day, or as directed.
To learn more about the best treatment options for different forms of hyperpigmentation and get started with your personalized treatment plan with Dr